array(41) {
["request_overridden_res"]=>
string(1) "3"
["project_status"]=>
string(30) "approved_pending_dua_signature"
["project_assoc_trials"]=>
array(2) {
[0]=>
object(WP_Post)#5841 (24) {
["ID"]=>
int(1249)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2014-10-20 14:57:00"
["post_date_gmt"]=>
string(19) "2014-10-20 14:57:00"
["post_content"]=>
string(0) ""
["post_title"]=>
string(233) "NCT00638690 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(193) "nct00638690-a-phase-3-randomized-double-blind-placebo-controlled-study-of-abiraterone-acetate-cb7630-plus-prednisone-in-patients-with-metastatic-castration-resistant-prostate-cancer-who-have-fa"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-10-24 14:58:34"
["post_modified_gmt"]=>
string(19) "2025-10-24 18:58:34"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(242) "https://dev-yoda.pantheonsite.io/clinical-trial/nct00638690-a-phase-3-randomized-double-blind-placebo-controlled-study-of-abiraterone-acetate-cb7630-plus-prednisone-in-patients-with-metastatic-castration-resistant-prostate-cancer-who-have-fa/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[1]=>
object(WP_Post)#5840 (24) {
["ID"]=>
int(1788)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2019-03-18 11:46:00"
["post_date_gmt"]=>
string(19) "2019-03-18 11:46:00"
["post_content"]=>
string(0) ""
["post_title"]=>
string(237) "NCT01695135 - A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(193) "nct01695135-a-phase-3-randomized-double-blind-placebo-controlled-study-of-abiraterone-acetate-jnj-212082-plus-prednisone-in-patients-with-metastatic-castration-resistant-prostate-cancer-who-hav"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-10-24 15:06:39"
["post_modified_gmt"]=>
string(19) "2025-10-24 19:06:39"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(242) "https://dev-yoda.pantheonsite.io/clinical-trial/nct01695135-a-phase-3-randomized-double-blind-placebo-controlled-study-of-abiraterone-acetate-jnj-212082-plus-prednisone-in-patients-with-metastatic-castration-resistant-prostate-cancer-who-hav/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
}
["project_title"]=>
string(148) "External validation of baseline and dynamic prognostic models for overall survival in post-docetaxel metastatic castration-resistant prostate cancer"
["project_narrative_summary"]=>
string(826) "Men with advanced prostate cancer that has grown after docetaxel chemotherapy differ widely in how long they live. Reliable estimates of each patient's outlook help researchers design fair clinical trials, balance treatment groups, and interpret results. We previously built two prediction models from the control groups of completed trials: one uses routine measurements taken before treatment, and one updates the prediction 120 days later using routine blood test results. Both worked well in two independent trials. This project tests the models, without changing them, in the control groups of further trials from different sponsors, countries, and years, and checks whether they also work in patients who received active treatment. No treatment effect will be estimated. The results will be published whatever they show."
["project_learn_source"]=>
string(4) "conf"
["principal_investigator"]=>
array(7) {
["first_name"]=>
string(5) "Yilun"
["last_name"]=>
string(3) "Sun"
["degree"]=>
string(3) "PhD"
["primary_affiliation"]=>
string(24) "Astellas Pharma US, Inc."
["email"]=>
string(22) "yilun.sun@astellas.com"
["state_or_province"]=>
string(2) "IL"
["country"]=>
string(13) "United States"
}
["project_key_personnel"]=>
bool(false)
["project_ext_grants"]=>
array(2) {
["value"]=>
string(2) "no"
["label"]=>
string(68) "No external grants or funds are being used to support this research."
}
["project_date_type"]=>
string(18) "full_crs_supp_docs"
["property_scientific_abstract"]=>
string(1512) "Background: Prognostic models for overall survival (OS) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC) support trial stratification, covariate adjustment, and cross-trial comparison. We developed a baseline Cox model using routine clinical and laboratory characteristics and a dynamic landmark Cox model that updates the prediction at day 120 using routine laboratory history; both were validated in two independent trials.
Objective: To externally validate both frozen models in additional trials and to test whether they hold in treated arms.
Study Design: Retrospective external validation using individual participant data; the models are applied without refitting.
Participants: Comparator arms of ELM-PC 5 (placebo plus prednisone; primary cohort), the abiraterone China bridging study (placebo plus prednisone), and CARD (abiraterone or enzalutamide); secondarily, the treated arms of these trials and the abiraterone arm of COU-AA-301.
Primary and Secondary Outcome Measures: Primary: 18-month time-dependent AUC of the baseline model, and the paired 12-month AUC difference between the dynamic and baseline models among day-120 survivors. Secondary: AUC at other horizons, Uno's C, Brier score, calibration slope, and observed-to-expected ratio.
Statistical Analysis: Inverse-probability-of-censoring-weighted time-dependent AUC; 95% bootstrap intervals from 1,000 resamples; cohort-specific estimates pooled by random-effects meta-analysis."
["project_brief_bg"]=>
string(2388) "Patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progresses after docetaxel have heterogeneous survival. Baseline prognostic models are used to stratify randomization, to adjust treatment comparisons for prognostic covariates, to compare patient populations across trials, and to benchmark external controls. Established models for this setting (Halabi 2013; Chi 2016) achieve useful discrimination; however, they depend partly on treatment-history inputs that are often unavailable in contemporary datasets, and they use laboratory values only once, at baseline, although the same markers are measured repeatedly during follow-up.
We developed two models to address these gaps. The baseline model is a Cox model using routinely collected clinical and laboratory characteristics. It was developed on the comparator arms of two completed phase 3 trials under internal-external cross-validation (18-month time-dependent AUC 0.79) and validated in the comparator arms of two further independent trials (18-month AUC 0.81 and 0.76). The dynamic model is a landmark Cox model (van Houwelingen 2007) that updates the baseline prediction at day 120 using changes and trends in routine laboratory markers; in prior external validation it improved 12-month discrimination among day-120 survivors by 0.072 (95% CI 0.031 to 0.122).
Prediction models must be validated repeatedly in independent data before they can be relied on, because performance commonly changes with case mix, era, and measurement practice (Collins 2015; Riley 2024). The requested trials differ from the development data in sponsor, geography (a bridging study conducted in China), era, and treatment context (a later line after a prior androgen-receptor-targeted agent in CARD), which makes them informative tests of transportability. Applying the models within treated arms tests whether the prognostic ranking holds under active therapy, a requirement for their use in covariate adjustment of randomized comparisons.
The results, positive or negative, will show whether models built from routinely collected data can serve as a common prognostic standard for the design and analysis of trials in this setting, and whether laboratory history adds prognostic information beyond baseline in independent populations. All findings will be published."
["project_specific_aims"]=>
string(1459) "Aim 1. Estimate the discrimination and calibration of the frozen baseline model in each comparator cohort: 18-month time-dependent AUC (primary); 12- and 24-month AUC, Uno's C, integrated Brier score, calibration slope, and observed-to-expected ratio, before and after recalibration (secondary). H1: the 18-month AUC exceeds 0.70 in the ELM-PC 5 comparator arm, consistent with prior development (0.79) and external (0.81) estimates.
Aim 2. Among patients alive and uncensored at day 120, estimate the 12-month AUC of the dynamic model and its paired difference from the baseline model. H2: the difference exceeds zero, with the lower 95% confidence limit above zero, consistent with a prior external gain of 0.072.
Aim 3. Characterize heterogeneity across comparator cohorts that differ in era, geography, and treatment context, with cohort-specific and random-effects pooled estimates; secondarily, apply both models within each treated arm, reported separately by arm.
Aim 4. Compare the computability and discrimination of the published Halabi 2013 and Chi 2016 scores with those of the baseline model where inputs exist.
Aim 5 (exploratory). Assess whether treatment-history characteristics omitted by the models (such as time from docetaxel to progression and prior hormonal therapy) add prognostic information.
All analyses are prognostic; no model includes treatment assignment, and no treatment effect is estimated."
["project_study_design"]=>
array(2) {
["value"]=>
string(5) "other"
["label"]=>
string(5) "Other"
}
["project_study_design_exp"]=>
string(116) "External validation of two existing prognostic models in multiple trials, with cohort-specific and pooled estimates."
["project_purposes"]=>
array(3) {
[0]=>
array(2) {
["value"]=>
string(22) "participant_level_data"
["label"]=>
string(36) "Participant-level data meta-analysis"
}
[1]=>
array(2) {
["value"]=>
string(56) "participant_level_data_meta_analysis_from_yoda_and_other"
["label"]=>
string(69) "Meta-analysis using data from the YODA Project and other data sources"
}
[2]=>
array(2) {
["value"]=>
string(50) "research_on_clinical_prediction_or_risk_prediction"
["label"]=>
string(50) "Research on clinical prediction or risk prediction"
}
}
["project_research_methods"]=>
string(1463) "Requested from the YODA Project: NCT00638690 (COU-AA-301) and NCT01695135 (abiraterone China bridging study). Inclusion: all randomized patients with known overall survival time and status. Exclusion: none.
Use by arm: the bridging study placebo-plus-prednisone arm is a secondary validation cohort, and its abiraterone arm a treated-arm cohort. The COU-AA-301 abiraterone arm is a treated-arm cohort; its placebo arm is not independent of prior model development and is used only descriptively, excluded from all validation analyses.
Other studies, requested in parallel through Vivli (request 00017810): ELM-PC 5 (NCT01193257; Takeda), the primary validation cohort, and CARD (NCT02485691; Sanofi), a secondary cohort. All participant-level analyses will be conducted within the Vivli secure research environment, where the YODA data packages are provided if both requests are approved; cohort-specific estimates computed there are pooled by random-effects meta-analysis within the platform.
No studies or data other than those named in this request will be analyzed, and no results will be combined with data from other studies outside the Vivli platform. The only material brought into the Vivli environment will be the frozen model specification (coefficient tables, baseline survival curves, and R scoring code), which contains aggregate estimates and no individual-level data; estimates from earlier work are cited for comparison only."
["project_main_outcome_measure"]=>
string(921) "Primary outcome: overall survival, defined as the time from randomization to death from any cause; patients alive at last contact are censored at the last known alive date. For the baseline model, OS is evaluated from randomization at 12, 18, and 24 months. For the dynamic model, OS is evaluated from the day-120 landmark among patients alive and uncensored at day 120, at 6, 12, and 18 months after the landmark. No other clinical outcome (progression, response, or adverse events) is analyzed.
Performance measures: inverse-probability-of-censoring-weighted time-dependent AUC (cumulative/dynamic definition), Uno's C, Brier score and integrated Brier score, calibration slope, O/E ratio, and calibration plots by risk decile. Each measure is reported with a 95% percentile bootstrap confidence interval from 1,000 patient-level resamples, and each horizon is reported with the number of patients still at risk."
["project_main_predictor_indep"]=>
string(962) "The frozen linear predictor of the baseline model, a prespecified combination of routinely collected characteristics measured at or before randomization: performance status, standard laboratory markers of disease burden, inflammation, and general health, sites of metastatic disease, and symptom-related medication use. Selected laboratory values are standardized to each trial's laboratory-specific reference ranges. Where a trial did not collect some of the laboratory markers, a prespecified reduced panel is applied instead.
For the dynamic model, the additional predictors summarize the change from baseline in the same laboratory markers and the trend in selected markers, using only measurements dated on or before day 120, and are set to zero when no post-baseline value exists by day 120. All coefficients are fixed from prior development work and are not re-estimated. The full model specification can be provided to the review panel on request."
["project_other_variables_interest"]=>
string(1543) "Required for the baseline models: performance status; baseline laboratory results with units, collection dates, and reference ranges; baseline tumor assessments or lesion records giving the sites of metastatic disease; and concomitant medications and analgesic records (diaries or scores), with start and stop dates or ongoing status. Required for the dynamic model and its sensitivity analyses: all post-baseline laboratory results with test identifiers, specimen types, units, collection dates, visit identifiers, and reference ranges. Required for the outcome: dates of randomization, first dose, death (from any record, including survival follow-up, disposition, and adverse-event records), and last contact, and vital status. For cohort description, benchmark scores, and the exploratory aim: demographics, disease characteristics at study entry (including measurable disease), patient-reported pain, treatment assignment, and prior treatment history with dates (androgen deprivation, docetaxel and other chemotherapy, androgen-receptor-targeted agents, and progression on prior therapy). No additional variable enters either frozen model. To apply the models, we ask that the anonymized data keep one date offset per participant (or study days), laboratory results in standard units with reference ranges, coded medication names with start and end dates or ongoing status at baseline (including supplemental qualifier variables), coded lesion locations, and the randomization date, and that analysis datasets be included where available."
["project_stat_analysis_plan"]=>
string(4387) "Populations. Primary analyses use each trial's comparator arm: ELM-PC 5 placebo plus prednisone (about 365 patients; primary cohort), the China bridging study placebo plus prednisone (about 71), and CARD abiraterone or enzalutamide (126). All randomized patients with known OS time and status are included. Cohorts are analyzed separately and then pooled. Secondary generalizability analyses use the treated arms (CARD cabazitaxel, about 129; ELM-PC 5 orteronel, about 734; bridging study abiraterone, about 143; COU-AA-301 abiraterone, about 797), each analyzed separately and never pooled with a comparator arm. The COU-AA-301 placebo arm (about 398) is not independent of prior model development; it is excluded from all validation analyses and used only descriptively.
Baseline model. The frozen model (or its prespecified reduced panel where some laboratory markers were not collected) gives each patient's predicted survival at monthly horizons from 1 to 24 months. Discrimination: inverse-probability-of-censoring-weighted time-dependent AUC at 18 months (primary) and at 12 and 24 months, and Uno's C; a horizon is declared not estimable when fewer than 20 patients remain at risk. Prediction error: Brier score at each horizon and integrated Brier score over 1 to 24 months, compared with a Kaplan-Meier null. Calibration: calibration slope on the complementary log-log scale with censoring weights, observed-to-expected (O/E) ratio, and decile calibration plots, before and after recalibration of intercept and slope. Success criterion: an 18-month AUC point estimate of at least 0.70; calibration is reported descriptively.
Dynamic model. Among patients alive and uncensored at day 120, features are computed only from laboratory records dated on or before day 120 (current values, changes from baseline, and marker trends, with structural zeros when no post-baseline value exists). The dynamic and frozen baseline models are compared by the paired difference in 12-month AUC from the landmark (primary), with 6- and 18-month AUC, Brier score, calibration slope, and O/E ratio as secondary measures. Sensitivity analyses address informative unscheduled sampling (protocol-scheduled visits only), dependence on feature-history length (42-day window), and imputation (complete-case baseline covariates).
Missing data. Missingness is tabulated per cohort before modeling. The primary analysis completes missing baseline predictors with the completion values that are part of the frozen model specification (development means, proportions for binary predictors, and the modal performance-status category), as in the prior external validation of the baseline model; sensitivity analyses use complete cases and multiple imputation by chained equations (m=20). Outcomes are never imputed.
Uncertainty and pooling. All measures carry 95% percentile bootstrap intervals from 1,000 patient-level resamples, with paired contrasts resampled jointly. Cohort estimates are pooled by random-effects meta-analysis (restricted maximum likelihood with the Hartung-Knapp adjustment), with between-cohort heterogeneity reported. Bridging-study results are expected to be imprecise and will be interpreted cautiously.
Treated arms. The same fixed models and measures are applied within each treated arm and reported separately by arm; no model includes treatment assignment, so no treatment effect is estimated. These results are exploratory.
Exploratory analysis. Within each cohort, a Cox model of OS on the frozen linear predictor plus the treatment-history characteristics of Aim 5 estimates their added prognostic information as hazard ratios and as the change in 18-month AUC, with bootstrap intervals. This analysis is hypothesis-generating; no updated coefficients will be exported or deployed.
Benchmarks. The Halabi 2013 and Chi 2016 scores are computed from observed data where inputs exist; computability and discrimination among scoreable patients are reported.
Software and environment. Analyses use R (survival, timeROC, mice, metafor) within the Vivli secure research environment. Only the frozen model specification (plain-text coefficient tables, baseline survival curves, and scoring code) is uploaded, and only aggregate results are exported. Any deviation from this plan will be documented and reported with the results."
["project_software_used"]=>
array(1) {
[0]=>
array(2) {
["value"]=>
string(1) "r"
["label"]=>
string(1) "R"
}
}
["project_timeline"]=>
string(1037) "Anticipated project start: February 2027, after approval of the parallel YODA and Vivli requests and provision of the data in the Vivli research environment.
Months 1 to 3: harmonization of variables across the four trials and verification that the frozen scoring code reproduces reference predictions in the Vivli environment.
Months 4 to 9: primary and secondary analyses (Aims 1 to 3).
Months 10 to 12: benchmark, exploratory, and sensitivity analyses (Aims 4 and 5); primary analyses completed by February 2028.
Manuscript drafted: May 2028. Manuscript first submitted for publication: July 2028.
Analysis completion date: February 2029. The Vivli analysis window runs to February 2029 to allow re-analysis during peer review, which must take place in the secure environment; one 12-month extension of the YODA Data Use Agreement will therefore be requested.
Results reported to the YODA Project: abstract and manuscript at the time of submission, and a results report at project completion."
["project_dissemination_plan"]=>
string(978) "Results will be reported in one peer-reviewed manuscript following the TRIPOD statement for external validation studies, with a conference abstract (for example, the ASCO Genitourinary Cancers Symposium). Candidate journals include JAMA Network Open, JCO Clinical Cancer Informatics, European Urology Oncology, and Prostate Cancer and Prostatic Diseases. Negative or attenuated results will be published equally. The target audience is clinical trialists, biostatisticians, and prostate cancer researchers. The publication will report each cohort separately and pooled, will include the YODA Project acknowledgment statement and request number, will acknowledge Vivli and the data contributors (Johnson & Johnson, Sanofi, Takeda), and will disclose the Lead Investigator's employment. Abstracts and manuscripts will be provided to the YODA Project at submission, and a results report at completion. No individual-level data will be used for any purpose beyond this proposal."
["project_bibliography"]=>
string(2233) "1. Halabi S, Lin CY, Small EJ, et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013;105:1729-1737.
2. Chi KN, Kheoh T, Ryan CJ, et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2016;27:454-460.
3. Fizazi K, Jones R, Oudard S, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC
5. J Clin Oncol. 2015;33:723-731.
4. Sun Y, Zou Q, Sun Z, et al. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: a randomized, double-blind, placebo-controlled phase 3 bridging study. Int J Urol. 2016;23:404-411. 5. de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381:2506-2518. 6. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005. 7. van Houwelingen HC. Dynamic prediction by landmarking in event history analysis. Scand J Stat. 2007;34:70-85.
8. Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32:5381-5397.
9. Uno H, Cai T, Pencina MJ, D’Agostino RB, Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011;30:1105-1117.
10. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD). BMJ. 2015;350:g7594.
11. Riley RD, Archer L, Snell KIE, et al. Evaluation of clinical prediction models (part 2): how to undertake an external validation study. BMJ. 2024;384:e074820.
"
["project_suppl_material"]=>
bool(false)
["project_coi"]=>
array(1) {
[0]=>
array(1) {
["file_coi"]=>
array(21) {
["ID"]=>
int(20281)
["id"]=>
int(20281)
["title"]=>
string(12) "COI_YODA.pdf"
["filename"]=>
string(12) "COI_YODA.pdf"
["filesize"]=>
int(49056)
["url"]=>
string(61) "https://yoda.yale.edu/wp-content/uploads/2026/10/COI_YODA.pdf"
["link"]=>
string(60) "https://yoda.yale.edu/data-request/2026-1088/coi_yoda-pdf-5/"
["alt"]=>
string(0) ""
["author"]=>
string(4) "2402"
["description"]=>
string(0) ""
["caption"]=>
string(0) ""
["name"]=>
string(14) "coi_yoda-pdf-5"
["status"]=>
string(7) "inherit"
["uploaded_to"]=>
int(20236)
["date"]=>
string(19) "2026-10-19 20:41:05"
["modified"]=>
string(19) "2026-10-19 20:41:07"
["menu_order"]=>
int(0)
["mime_type"]=>
string(15) "application/pdf"
["type"]=>
string(11) "application"
["subtype"]=>
string(3) "pdf"
["icon"]=>
string(62) "https://yoda.yale.edu/wp/wp-includes/images/media/document.png"
}
}
}
["data_use_agreement_training"]=>
bool(true)
["human_research_protection_training"]=>
bool(true)
["certification"]=>
bool(true)
["search_order"]=>
string(1) "0"
["project_send_email_updates"]=>
bool(false)
["project_publ_available"]=>
bool(true)
["project_year_access"]=>
string(0) ""
["project_rep_publ"]=>
bool(false)
["project_assoc_data"]=>
array(0) {
}
["project_due_dil_assessment"]=>
bool(false)
["project_title_link"]=>
array(21) {
["ID"]=>
int(19765)
["id"]=>
int(19765)
["title"]=>
string(28) "Data Request Approved Notice"
["filename"]=>
string(32) "Data-Request-Approved-Notice.pdf"
["filesize"]=>
int(195663)
["url"]=>
string(81) "https://yoda.yale.edu/wp-content/uploads/2026/07/Data-Request-Approved-Notice.pdf"
["link"]=>
string(77) "https://yoda.yale.edu/data-request/2026-0640/data-request-approved-notice-72/"
["alt"]=>
string(0) ""
["author"]=>
string(4) "1885"
["description"]=>
string(0) ""
["caption"]=>
string(0) ""
["name"]=>
string(31) "data-request-approved-notice-72"
["status"]=>
string(7) "inherit"
["uploaded_to"]=>
int(19689)
["date"]=>
string(19) "2026-08-06 16:54:58"
["modified"]=>
string(19) "2026-08-06 16:54:58"
["menu_order"]=>
int(0)
["mime_type"]=>
string(15) "application/pdf"
["type"]=>
string(11) "application"
["subtype"]=>
string(3) "pdf"
["icon"]=>
string(62) "https://yoda.yale.edu/wp/wp-includes/images/media/document.png"
}
["project_review_link"]=>
bool(false)
["project_highlight_button"]=>
string(0) ""
["request_data_partner"]=>
string(0) ""
}
data partner
array(1) {
[0]=>
string(0) ""
}
pi country
array(0) {
}
pi affil
array(0) {
}
products
array(0) {
}
num of trials
array(1) {
[0]=>
string(1) "0"
}
res
array(1) {
[0]=>
string(1) "3"
}
Research Proposal
Project Title:
External validation of baseline and dynamic prognostic models for overall survival in post-docetaxel metastatic castration-resistant prostate cancer
Scientific Abstract:
Background: Prognostic models for overall survival (OS) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC) support trial stratification, covariate adjustment, and cross-trial comparison. We developed a baseline Cox model using routine clinical and laboratory characteristics and a dynamic landmark Cox model that updates the prediction at day 120 using routine laboratory history; both were validated in two independent trials.
Objective: To externally validate both frozen models in additional trials and to test whether they hold in treated arms.
Study Design: Retrospective external validation using individual participant data; the models are applied without refitting.
Participants: Comparator arms of ELM-PC 5 (placebo plus prednisone; primary cohort), the abiraterone China bridging study (placebo plus prednisone), and CARD (abiraterone or enzalutamide); secondarily, the treated arms of these trials and the abiraterone arm of COU-AA-301.
Primary and Secondary Outcome Measures: Primary: 18-month time-dependent AUC of the baseline model, and the paired 12-month AUC difference between the dynamic and baseline models among day-120 survivors. Secondary: AUC at other horizons, Uno's C, Brier score, calibration slope, and observed-to-expected ratio.
Statistical Analysis: Inverse-probability-of-censoring-weighted time-dependent AUC; 95% bootstrap intervals from 1,000 resamples; cohort-specific estimates pooled by random-effects meta-analysis.
Brief Project Background and Statement of Project Significance:
Patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progresses after docetaxel have heterogeneous survival. Baseline prognostic models are used to stratify randomization, to adjust treatment comparisons for prognostic covariates, to compare patient populations across trials, and to benchmark external controls. Established models for this setting (Halabi 2013; Chi 2016) achieve useful discrimination; however, they depend partly on treatment-history inputs that are often unavailable in contemporary datasets, and they use laboratory values only once, at baseline, although the same markers are measured repeatedly during follow-up.
We developed two models to address these gaps. The baseline model is a Cox model using routinely collected clinical and laboratory characteristics. It was developed on the comparator arms of two completed phase 3 trials under internal-external cross-validation (18-month time-dependent AUC 0.79) and validated in the comparator arms of two further independent trials (18-month AUC 0.81 and 0.76). The dynamic model is a landmark Cox model (van Houwelingen 2007) that updates the baseline prediction at day 120 using changes and trends in routine laboratory markers; in prior external validation it improved 12-month discrimination among day-120 survivors by 0.072 (95% CI 0.031 to 0.122).
Prediction models must be validated repeatedly in independent data before they can be relied on, because performance commonly changes with case mix, era, and measurement practice (Collins 2015; Riley 2024). The requested trials differ from the development data in sponsor, geography (a bridging study conducted in China), era, and treatment context (a later line after a prior androgen-receptor-targeted agent in CARD), which makes them informative tests of transportability. Applying the models within treated arms tests whether the prognostic ranking holds under active therapy, a requirement for their use in covariate adjustment of randomized comparisons.
The results, positive or negative, will show whether models built from routinely collected data can serve as a common prognostic standard for the design and analysis of trials in this setting, and whether laboratory history adds prognostic information beyond baseline in independent populations. All findings will be published.
Specific Aims of the Project:
Aim 1. Estimate the discrimination and calibration of the frozen baseline model in each comparator cohort: 18-month time-dependent AUC (primary); 12- and 24-month AUC, Uno's C, integrated Brier score, calibration slope, and observed-to-expected ratio, before and after recalibration (secondary). H1: the 18-month AUC exceeds 0.70 in the ELM-PC 5 comparator arm, consistent with prior development (0.79) and external (0.81) estimates.
Aim 2. Among patients alive and uncensored at day 120, estimate the 12-month AUC of the dynamic model and its paired difference from the baseline model. H2: the difference exceeds zero, with the lower 95% confidence limit above zero, consistent with a prior external gain of 0.072.
Aim 3. Characterize heterogeneity across comparator cohorts that differ in era, geography, and treatment context, with cohort-specific and random-effects pooled estimates; secondarily, apply both models within each treated arm, reported separately by arm.
Aim 4. Compare the computability and discrimination of the published Halabi 2013 and Chi 2016 scores with those of the baseline model where inputs exist.
Aim 5 (exploratory). Assess whether treatment-history characteristics omitted by the models (such as time from docetaxel to progression and prior hormonal therapy) add prognostic information.
All analyses are prognostic; no model includes treatment assignment, and no treatment effect is estimated.
Study Design:
Other
Explain:
External validation of two existing prognostic models in multiple trials, with cohort-specific and pooled estimates.
What is the purpose of the analysis being proposed? Please select all that apply.:
Participant-level data meta-analysis
Meta-analysis using data from the YODA Project and other data sources
Research on clinical prediction or risk prediction
Software Used:
R
Data Source and Inclusion/Exclusion Criteria to be used to define the patient sample for your study:
Requested from the YODA Project: NCT00638690 (COU-AA-301) and NCT01695135 (abiraterone China bridging study). Inclusion: all randomized patients with known overall survival time and status. Exclusion: none.
Use by arm: the bridging study placebo-plus-prednisone arm is a secondary validation cohort, and its abiraterone arm a treated-arm cohort. The COU-AA-301 abiraterone arm is a treated-arm cohort; its placebo arm is not independent of prior model development and is used only descriptively, excluded from all validation analyses.
Other studies, requested in parallel through Vivli (request 00017810): ELM-PC 5 (NCT01193257; Takeda), the primary validation cohort, and CARD (NCT02485691; Sanofi), a secondary cohort. All participant-level analyses will be conducted within the Vivli secure research environment, where the YODA data packages are provided if both requests are approved; cohort-specific estimates computed there are pooled by random-effects meta-analysis within the platform.
No studies or data other than those named in this request will be analyzed, and no results will be combined with data from other studies outside the Vivli platform. The only material brought into the Vivli environment will be the frozen model specification (coefficient tables, baseline survival curves, and R scoring code), which contains aggregate estimates and no individual-level data; estimates from earlier work are cited for comparison only.
Primary and Secondary Outcome Measure(s) and how they will be categorized/defined for your study:
Primary outcome: overall survival, defined as the time from randomization to death from any cause; patients alive at last contact are censored at the last known alive date. For the baseline model, OS is evaluated from randomization at 12, 18, and 24 months. For the dynamic model, OS is evaluated from the day-120 landmark among patients alive and uncensored at day 120, at 6, 12, and 18 months after the landmark. No other clinical outcome (progression, response, or adverse events) is analyzed.
Performance measures: inverse-probability-of-censoring-weighted time-dependent AUC (cumulative/dynamic definition), Uno's C, Brier score and integrated Brier score, calibration slope, O/E ratio, and calibration plots by risk decile. Each measure is reported with a 95% percentile bootstrap confidence interval from 1,000 patient-level resamples, and each horizon is reported with the number of patients still at risk.
Main Predictor/Independent Variable and how it will be categorized/defined for your study:
The frozen linear predictor of the baseline model, a prespecified combination of routinely collected characteristics measured at or before randomization: performance status, standard laboratory markers of disease burden, inflammation, and general health, sites of metastatic disease, and symptom-related medication use. Selected laboratory values are standardized to each trial's laboratory-specific reference ranges. Where a trial did not collect some of the laboratory markers, a prespecified reduced panel is applied instead.
For the dynamic model, the additional predictors summarize the change from baseline in the same laboratory markers and the trend in selected markers, using only measurements dated on or before day 120, and are set to zero when no post-baseline value exists by day 120. All coefficients are fixed from prior development work and are not re-estimated. The full model specification can be provided to the review panel on request.
Other Variables of Interest that will be used in your analysis and how they will be categorized/defined for your study:
Required for the baseline models: performance status; baseline laboratory results with units, collection dates, and reference ranges; baseline tumor assessments or lesion records giving the sites of metastatic disease; and concomitant medications and analgesic records (diaries or scores), with start and stop dates or ongoing status. Required for the dynamic model and its sensitivity analyses: all post-baseline laboratory results with test identifiers, specimen types, units, collection dates, visit identifiers, and reference ranges. Required for the outcome: dates of randomization, first dose, death (from any record, including survival follow-up, disposition, and adverse-event records), and last contact, and vital status. For cohort description, benchmark scores, and the exploratory aim: demographics, disease characteristics at study entry (including measurable disease), patient-reported pain, treatment assignment, and prior treatment history with dates (androgen deprivation, docetaxel and other chemotherapy, androgen-receptor-targeted agents, and progression on prior therapy). No additional variable enters either frozen model. To apply the models, we ask that the anonymized data keep one date offset per participant (or study days), laboratory results in standard units with reference ranges, coded medication names with start and end dates or ongoing status at baseline (including supplemental qualifier variables), coded lesion locations, and the randomization date, and that analysis datasets be included where available.
Statistical Analysis Plan:
Populations. Primary analyses use each trial's comparator arm: ELM-PC 5 placebo plus prednisone (about 365 patients; primary cohort), the China bridging study placebo plus prednisone (about 71), and CARD abiraterone or enzalutamide (126). All randomized patients with known OS time and status are included. Cohorts are analyzed separately and then pooled. Secondary generalizability analyses use the treated arms (CARD cabazitaxel, about 129; ELM-PC 5 orteronel, about 734; bridging study abiraterone, about 143; COU-AA-301 abiraterone, about 797), each analyzed separately and never pooled with a comparator arm. The COU-AA-301 placebo arm (about 398) is not independent of prior model development; it is excluded from all validation analyses and used only descriptively.
Baseline model. The frozen model (or its prespecified reduced panel where some laboratory markers were not collected) gives each patient's predicted survival at monthly horizons from 1 to 24 months. Discrimination: inverse-probability-of-censoring-weighted time-dependent AUC at 18 months (primary) and at 12 and 24 months, and Uno's C; a horizon is declared not estimable when fewer than 20 patients remain at risk. Prediction error: Brier score at each horizon and integrated Brier score over 1 to 24 months, compared with a Kaplan-Meier null. Calibration: calibration slope on the complementary log-log scale with censoring weights, observed-to-expected (O/E) ratio, and decile calibration plots, before and after recalibration of intercept and slope. Success criterion: an 18-month AUC point estimate of at least 0.70; calibration is reported descriptively.
Dynamic model. Among patients alive and uncensored at day 120, features are computed only from laboratory records dated on or before day 120 (current values, changes from baseline, and marker trends, with structural zeros when no post-baseline value exists). The dynamic and frozen baseline models are compared by the paired difference in 12-month AUC from the landmark (primary), with 6- and 18-month AUC, Brier score, calibration slope, and O/E ratio as secondary measures. Sensitivity analyses address informative unscheduled sampling (protocol-scheduled visits only), dependence on feature-history length (42-day window), and imputation (complete-case baseline covariates).
Missing data. Missingness is tabulated per cohort before modeling. The primary analysis completes missing baseline predictors with the completion values that are part of the frozen model specification (development means, proportions for binary predictors, and the modal performance-status category), as in the prior external validation of the baseline model; sensitivity analyses use complete cases and multiple imputation by chained equations (m=20). Outcomes are never imputed.
Uncertainty and pooling. All measures carry 95% percentile bootstrap intervals from 1,000 patient-level resamples, with paired contrasts resampled jointly. Cohort estimates are pooled by random-effects meta-analysis (restricted maximum likelihood with the Hartung-Knapp adjustment), with between-cohort heterogeneity reported. Bridging-study results are expected to be imprecise and will be interpreted cautiously.
Treated arms. The same fixed models and measures are applied within each treated arm and reported separately by arm; no model includes treatment assignment, so no treatment effect is estimated. These results are exploratory.
Exploratory analysis. Within each cohort, a Cox model of OS on the frozen linear predictor plus the treatment-history characteristics of Aim 5 estimates their added prognostic information as hazard ratios and as the change in 18-month AUC, with bootstrap intervals. This analysis is hypothesis-generating; no updated coefficients will be exported or deployed.
Benchmarks. The Halabi 2013 and Chi 2016 scores are computed from observed data where inputs exist; computability and discrimination among scoreable patients are reported.
Software and environment. Analyses use R (survival, timeROC, mice, metafor) within the Vivli secure research environment. Only the frozen model specification (plain-text coefficient tables, baseline survival curves, and scoring code) is uploaded, and only aggregate results are exported. Any deviation from this plan will be documented and reported with the results.
Narrative Summary:
Men with advanced prostate cancer that has grown after docetaxel chemotherapy differ widely in how long they live. Reliable estimates of each patient's outlook help researchers design fair clinical trials, balance treatment groups, and interpret results. We previously built two prediction models from the control groups of completed trials: one uses routine measurements taken before treatment, and one updates the prediction 120 days later using routine blood test results. Both worked well in two independent trials. This project tests the models, without changing them, in the control groups of further trials from different sponsors, countries, and years, and checks whether they also work in patients who received active treatment. No treatment effect will be estimated. The results will be published whatever they show.
Project Timeline:
Anticipated project start: February 2027, after approval of the parallel YODA and Vivli requests and provision of the data in the Vivli research environment.
Months 1 to 3: harmonization of variables across the four trials and verification that the frozen scoring code reproduces reference predictions in the Vivli environment.
Months 4 to 9: primary and secondary analyses (Aims 1 to 3).
Months 10 to 12: benchmark, exploratory, and sensitivity analyses (Aims 4 and 5); primary analyses completed by February 2028.
Manuscript drafted: May 2028. Manuscript first submitted for publication: July 2028.
Analysis completion date: February 2029. The Vivli analysis window runs to February 2029 to allow re-analysis during peer review, which must take place in the secure environment; one 12-month extension of the YODA Data Use Agreement will therefore be requested.
Results reported to the YODA Project: abstract and manuscript at the time of submission, and a results report at project completion.
Dissemination Plan:
Results will be reported in one peer-reviewed manuscript following the TRIPOD statement for external validation studies, with a conference abstract (for example, the ASCO Genitourinary Cancers Symposium). Candidate journals include JAMA Network Open, JCO Clinical Cancer Informatics, European Urology Oncology, and Prostate Cancer and Prostatic Diseases. Negative or attenuated results will be published equally. The target audience is clinical trialists, biostatisticians, and prostate cancer researchers. The publication will report each cohort separately and pooled, will include the YODA Project acknowledgment statement and request number, will acknowledge Vivli and the data contributors (Johnson & Johnson, Sanofi, Takeda), and will disclose the Lead Investigator's employment. Abstracts and manuscripts will be provided to the YODA Project at submission, and a results report at completion. No individual-level data will be used for any purpose beyond this proposal.
Bibliography:
1. Halabi S, Lin CY, Small EJ, et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013;105:1729-1737.
2. Chi KN, Kheoh T, Ryan CJ, et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2016;27:454-460.
3. Fizazi K, Jones R, Oudard S, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC
5. J Clin Oncol. 2015;33:723-731.
4. Sun Y, Zou Q, Sun Z, et al. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: a randomized, double-blind, placebo-controlled phase 3 bridging study. Int J Urol. 2016;23:404-411. 5. de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381:2506-2518. 6. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005. 7. van Houwelingen HC. Dynamic prediction by landmarking in event history analysis. Scand J Stat. 2007;34:70-85.
8. Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32:5381-5397.
9. Uno H, Cai T, Pencina MJ, D’Agostino RB, Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011;30:1105-1117.
10. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD). BMJ. 2015;350:g7594.
11. Riley RD, Archer L, Snell KIE, et al. Evaluation of clinical prediction models (part 2): how to undertake an external validation study. BMJ. 2024;384:e074820.